United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 2.5 mg in 1 ml - verapamil hydrochloride injection, usp is indicated for the following: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [w-p-w] and lown-ganong- levine [l-g-l] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white (w-p-w) and lown-ganong-levine (l-g-l) syndromes). in controlled studies in the united states, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flut

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 2.5 mg in 1 ml - verapamil hydrochloride injection, usp is indicated for the following: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [w-p-w] and lown-ganong- levine [l-g-l] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white (w-p-w) and lown-ganong-levine (l-g-l) syndromes). in controlled studies in the united states, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flut

United States - English - NLM (National Library of Medicine)

cardinal health - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 2.5 mg in 1 ml - verapamil hydrochloride injection, usp is indicated for the following: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [w-p-w] and lown-ganong- levine [l-g-l] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white (w-p-w) and lown-ganong-levine (l-g-l) syndromes). in controlled studies in the united states, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flutte

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - verapamil hydrochloride - tablet, film coated - 240 mg - verapamil hydrochloride 240.0 mg

United States - English - NLM (National Library of Medicine)

carilion materials management - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 180 mg - verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmaco

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - verapamil hydrochloride - film-coated tablet - 120 milligram(s) - phenylalkylamine derivatives; verapamil - selective calcium channel blockers with direct cardiac effects, phenylalkylamine - prophylaxis and/or treatment of:-
angina pectoris, including prinzmetal’s angina (coronary spasm, vasospastic angina).
supraventricular tachycardias such as paroxysmal supraventricular tachycardia, atrial fibrillation/flutter with rapid ventricular response (except in wpw syndrome, see “contraindications”).
mild to moderate essential hypertension

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - verapamil hydrochloride - prolonged-release tablet - 240 milligram(s) - phenylalkylamine derivatives; verapamil - selective calcium channel blockers with direct cardiac effects, phenylalkylamine - mild to moderate hypertension and coronary heart disease, i.e. prophylaxis of myocardial ischaemia, angina pectoris.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - verapamil hydrochloride - film-coated tablet - 40 milligram(s) - phenylalkylamine derivatives; verapamil - selective calcium channel blockers with direct cardiac effects, phenylalkylamine - prophylaxis and/or treatment of: angina pectoris, including prinzmetal’s angina (coronary spasm, vasospastic angina):; supraventricular tachycardias such as paroxysmal supraventricular tachycardia, atrial fibrillation/flutter with rapid ventricular response (except in wpw syndrome, see “contra-indications”); mild to moderate essential hypertension.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - verapamil hydrochloride - film-coated tablet - 80 milligram(s) - phenylalkylamine derivatives; verapamil

United States - English - NLM (National Library of Medicine)

exela pharma sciences, llc - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride 2.5 mg in 1 ml - verapamil is indicated for the treatment of supraventricular tachyarrhythmias, including: in controlled studies in the u.s., about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in heart rate of at least 20%. conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. the effect of a single injection lasts for 30–60 minutes when conversion to sinus rhythm does not occur. because a small fraction (<1.0%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation w